Ionis Reports Promising Phase 3 Results for Olezarsen in Severe Triglyceride Management

Ionis Pharmaceuticals announced positive Phase 3 results for olezarsen, significantly reducing fasting triglyceride levels in patients with severe hypertriglyceridemia, marking a potential breakthrough in managing risks associated with acute pancreatitis.

• In pivotal Phase 3 studies, olezarsen achieved a placebo-adjusted mean reduction of up to 72% in fasting triglyceride levels over six months in patients with severe hypertriglyceridemia.
• The trials not only met their primary clinical endpoint but also demonstrated that the triglyceride reductions were durable and consistent over a 12-month treatment period.
• The findings from the studies are set to be published in The New England Journal of Medicine, highlighting the drugs potential impact on reducing risks related to acute pancreatitis.